Mental Health

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

Those with an aneurysm diagnosis who were younger than 40 years of age were observed to have an even higher risk.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.

Zuranolone enhances health care providers’ ability to address the complex needs of patients with PPD, offering new hope for rapid and sustained relief from depressive symptoms.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

Patients with MDD may also seek complementary or alternative therapies in the form of dietary supplements which might be perceived by patients to be natural and safer than medicinal agents.

The study also found that there were no associations with increased dementia risk when anxiety resolved.

Although important for patient health care, pharmacies’ convenient locations leave staff prone to workplace violence.

Paliperidone palmitate (Erzofi; Luye Pharma Group) is approved as a monotherapy for schizophrenia and as an adjunct for schizoaffective disorder.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.

Acetylcholine deficit observed in patients with anorexia nervosa suggest potential targeted treatment options.

On a scale from 1 to 10, respondents rated their feelings of burnout an average of 7.25 in the second annual Pharmacy Times Burnout and Mental Health Survey.

The authors emphasize that these findings suggest a need for targeted resources that help reduce boarding and promote equitable access to care.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.

The American College of Clinical Gynecology recommends consideration of brexanolone or zuranolone in postpartum patients with onset of moderate-to-severe perinatal depression in the third trimester or within 4 weeks postpartum.

The findings suggest that exploring gender identity is a normal part of adolescent development for some youths.

Perinatal depression increases the risk of cardiovascular disease in women.

The supplemental new drug application (sNDA) for brexpiprazole is accepted by the FDA for treatment of patients with post-traumatic stress disorder (PTSD).

Although the committee's vote is non-binding, it does raise questions about optimal evaluation of psychedelics in clinical trials.

Creating a supportive environment and staying informed on the latest research can be significant when supporting patients in the LGBTQ+ community, notes Olivia Buckoski, PharmD, AAHIVP, HIVPCP.

Eating a poor diet might lead to structural brain changes that cause the development of common mental disorders (CMD).

Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.